Cercare Medical

Cercare Medical, founded in 2013 as a spin-off from Aarhus University, is a Danish company specializing in advanced neuroimaging software. The founders, Professor Kim Beuschau Mouridsen and Mikkel Bo Hansen, established the company based on over two decades of research in perfusion imaging and post-processing. Professor Mouridsen, who serves as the CEO, has an extensive background in neuroscience and artificial intelligence, with previous positions at Harvard Medical School and as head of Neuroimaging Methods at Aarhus University's MINDLab. The company's core technology is also rooted in the research of Professor Leif Østergaard, director of the Center for Functionally Integrative Neuroscience at Aarhus University, who has a long history in studying cerebrovascular physiology and developing scanning methods to assess brain tissue at risk from low blood flow.

The company's primary business is the development and sale of software solutions that analyze brain CT and MRI scans, serving healthcare professionals in hospitals and clinics. Its business model centers on providing these tools to enhance diagnostic capabilities and streamline radiological workflows for conditions like stroke, brain tumors, and neurodegenerative diseases such as Alzheimer's. Revenue is generated through the licensing of its software platforms. The company has demonstrated significant growth, reporting yearly triple-digit growth and expanding its presence to over 23 countries with more than 100 installations. A recent funding round in early 2025, led by West Hill Capital, raised €7.4 million to fuel expansion in the U.S., UK, and other European markets.

Cercare Medical’s main product is the Cercare Medical Neurosuite, a platform that uses AI-powered algorithms to automate the post-processing of perfusion imaging data from both CT and MRI scans. This software is vendor-neutral, ensuring compatibility with various imaging hardware. A key feature is its ability to generate unique, patented perfusion maps that visualize capillary function, oxygen metabolism, and blood flow, providing clinicians with a more detailed assessment of tissue viability. The suite includes specialized modules such as CERCARE Stroke, which aids in the rapid assessment of ischemic stroke by automatically segmenting infarct core and hypoperfused areas, and CERCARE Oncology for analyzing brain tumor progression. The technology has received FDA clearance for both MRI and CT perfusion imaging, marking significant regulatory milestones for the company. The company collaborates with major industry partners like Siemens, Aidoc, and SECTRA to integrate its solutions into existing clinical infrastructures.

Keywords: neuroimaging software, perfusion imaging, medical imaging AI, stroke diagnostics, brain scan analysis, oncology imaging, CT perfusion, MRI perfusion, Kim Beuschau Mouridsen, Leif Østergaard, Aarhus University spin-off, medical diagnostics, radiological workflow, brain tissue assessment, microvascular modeling, automated image analysis, clinical decision support, neurodegenerative diseases, brain tumor analysis, ischemic stroke